Sweden-based biotechnology company SmartCella Holding AB announced on Wednesday that it held its 2024 Annual General Meeting on 10 June, where it introduced several new board members who all hold unique life science industry and medical expertise.

The company said that the newly appointed board of directors will play a pivotal role as SmartCella embarks on its next strategic development phase.

At the Annual General Meeting, Anna Martling (professor of Surgery and scientific director Life Science at Karolinska Institutet), Claude Dartiguelongue (previously senior roles with Lonza, Thermo Fisher Scientific and Becton Dickinson and Company), and Regina Fritsche-Danielson (PhD in Cardiovascular Physiology/Pharmacology and senior vice president and global head of Research and Early Development, Cardiovascular, Renal and Metabolic Diseases at AstraZeneca) were appointed new members of the SmartCella board of directors. Magnus Tornling, partner and global head of Equity Capital Markets at private equity firm EQT, and Christian Kinch, founder and chairperson, were re-elected. Thomas von Koch declined re-election.

Christian Kinch, SmartCella chairperson commented 'We founded SmartCella in 2014 and have since invested in science, clinical data, team development, and infrastructure. As we advance on our strategic journey, our new board members will bring immense value with their diverse backgrounds in academia, science, and the commercial aspects of global MedTech and life science companies. It is a testament to our strength that we can attract such high-calibre individuals to the board, whose skills complement SmartCella's strong in-house team. I am excited and humbled by the potential of our collaboration and the impact SmartCella can have in addressing global health challenges, such as cardiovascular diseases and cancer. Our goal is to bring the magic behind medical science to transform lives, and I could not have a better board of directors to help achieve this vision.' He continues: 'I would like to extend my appreciation to Thomas von Koch for his dedication and support over the past ten years. His philosophy of future-proofing companies has significantly contributed to SmartCella's development. We look forward to continuing our collaboration with Thomas as an advisor and anchor investor.'